Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 relative bioavailability, food effect, and multiple-dose safety study of S-337395 in Japanese healthy adults and elderly participants
jRCT2031240405Phase 1Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of S-337395 in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Maximum plasma concentration, Plasma concentration at 24 hours and 13 more. Started Oct 2024; status: recruiting.
02
Drugs
S-337395
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031240405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240405.